About
Anti-angiogenic and Immune Modulatory Platforms for Cancer Treatment
Tiltan Pharma is a biopharmaceutical company that developed a proprietary anti-angiogenic and immune modulatory platform for the treatment of cancer. The company'sleading product, TL-118, is an oral drug combination with anticancer, anti-angiogenic, and immune modulatory properties. TL-118 repurposes four approved drugs with known safety profiles, combined as an anticancer therapy in a low-dose, high-frequency regimen. TL-118 has beentested in numerous animal tumor models and over 150 cancer patients. Tiltan is conducting a randomized, open-label phase-IIb clinical trial in metastatic pancreatic cancer under an FDA-approved investigational new drug application. The trial is being conducted in Israel and Eastern Europe as well as in US investigator-initiated studies.
Identity
| Name | Tiltan Pharma |
|---|---|
| Slug | tiltan-pharma |
| Type / kind | startup |
| Crunchbase ID | tiltan-pharma |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6_pI4KDA |
Status
| Status | inactive |
|---|---|
| Status reason | Non Active, Sep 2019 ceased to operate |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Jerusalem District |
| HQ city | Jerusalem |
| HQ address | Givat Ram, 91390, Jerusalem, Israel |
Web & social
| Website | http://tiltanpharma.com |
|---|---|
| https://www.linkedin.com/company/8082660 |
Classifications
Funding
| Total raised | $1.5M |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}